Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pacific Biosciences (PACB)

Pacific Biosciences (PACB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 477,013
  • Shares Outstanding, K 301,907
  • Annual Sales, $ 160,010 K
  • Annual Income, $ -546,380 K
  • EBIT $ -134 M
  • EBITDA $ -47 M
  • 60-Month Beta 2.27
  • Price/Sales 3.23
  • Price/Cash Flow N/A
  • Price/Book 14.23

Options Overview Details

View History
  • Implied Volatility 117.52% (+6.61%)
  • Historical Volatility 88.79%
  • IV Percentile 57%
  • IV Rank 10.39%
  • IV High 412.87% on 04/16/25
  • IV Low 83.27% on 08/25/25
  • Expected Move (DTE 1) 0.2550 (15.64%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 1,583
  • Volume Avg (30-Day) 1,408
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 73,073
  • Open Int (30-Day) 67,640
  • Expected Range 1.3750 to 1.8850

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -13.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5100 +7.95%
on 02/17/26
2.7300 -40.29%
on 01/23/26
-0.5800 (-26.24%)
since 01/16/26
3-Month
1.5100 +7.95%
on 02/17/26
2.7300 -40.29%
on 01/23/26
-0.0200 (-1.21%)
since 11/18/25
52-Week
0.8500 +91.76%
on 05/28/25
2.7300 -40.29%
on 01/23/26
-0.2400 (-12.83%)
since 02/18/25

Most Recent Stories

More News
PacBio to Participate in the TD Cowen 46th Annual Health Care Conference 

MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate...

PACB : 1.6300 (+3.16%)
1 Safe-and-Steady Stock with Impressive Fundamentals and 2 We Avoid

1 Safe-and-Steady Stock with Impressive Fundamentals and 2 We Avoid

PACB : 1.6300 (+3.16%)
BYD : 84.75 (+1.84%)
ADP : 217.21 (+1.94%)
PACB Q4 Deep Dive: Consumables and Clinical Adoption Drive Growth as SparkNex Launch Nears

PACB Q4 Deep Dive: Consumables and Clinical Adoption Drive Growth as SparkNex Launch Nears

PACB : 1.6300 (+3.16%)
PacBio (NASDAQ:PACB) Reports Strong Q4 CY2025

PacBio (NASDAQ:PACB) Reports Strong Q4 CY2025

PACB : 1.6300 (+3.16%)
Pacific Biosciences: Q4 Earnings Snapshot

Pacific Biosciences: Q4 Earnings Snapshot

PACB : 1.6300 (+3.16%)
PacBio Announces Fourth Quarter and Full Year 2025 Financial Results

MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year...

PACB : 1.6300 (+3.16%)
PacBio Joins iHope Initiative as First Long-Read Genomic Sequencing Partner

MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced a collaboration with iHope, a global...

PACB : 1.6300 (+3.16%)
PacBio Earnings: What To Look For From PACB

PacBio Earnings: What To Look For From PACB

PACB : 1.6300 (+3.16%)
3 Cash-Burning Stocks We Approach with Caution

3 Cash-Burning Stocks We Approach with Caution

LOVE : 13.64 (+1.34%)
JELD : 2.46 (+17.14%)
PACB : 1.6300 (+3.16%)
PacBio Completes Sale of Short-Read Sequencing Assets

MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select...

PACB : 1.6300 (+3.16%)

Business Summary

Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA. PacBio's products are based on Single Molecule, Real-Time...

See More

Key Turning Points

3rd Resistance Point 1.8833
2nd Resistance Point 1.7967
1st Resistance Point 1.7133
Last Price 1.6300
1st Support Level 1.5433
2nd Support Level 1.4567
3rd Support Level 1.3733

See More

52-Week High 2.7300
Fibonacci 61.8% 2.0118
Fibonacci 50% 1.7900
Last Price 1.6300
Fibonacci 38.2% 1.5682
52-Week Low 0.8500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar